A mobile compendium of hepatology assessment tools, an app to help select the right treatment regimen, and 3 more liver apps for primary care.
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
Your daily dose of the clinical news you may have missed.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Sen-Jam Pharmaceutical Reports Preliminary Phase 2 Results for SJP-002C in COVID-19 Treatment
The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.
FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning
The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.